Towards Healthcare

Noom Launches Microdose GLP-1 Program to Help People Lose Weight with Fewer Side Effects

Noom introduces a new microdose GLP-1 weight loss program that aims to reduce side effects, promote sustainable habits, and make obesity treatment more affordable and effective.

Author: Towards Healthcare Published Date: 7 August 2025
Share : linkedin twitter facebook

Noom’s New Microdose GLP-1 Program Aims to Tackle Obesity

Noom introduces microdose GLP-1 weight loss program with reduced side effects

Announcement

The Noom, a well-established digital healthcare company focused on chronic disease prevention and encouraging people to live a quality and longer life, launched the Noom microdose GLP-1program, a commendable initiative providing long-term health and weight-loss benefits with fewer side effects via personalized microdoses of GLP-1 medication, in clinical accuracy cases. The Microsoft GLP-1 program costs $119 to start and is followed by $199 per month, including medications (if prescribed. Also, Noom’s robust GLP-1 support enables clinical care and a personalized healthy habit and coaching program.

Obesity Concern

The obesity rate of the US, after years of uncontrolled growth, started to rise above, but at a level that allowed consistency, leading the developed world. The US rate of obesity is more than 40% and 26% in the UK, France at 10% and Germany at 23%. While the GLP-1 price is greater as 5x greater in the US in comparison much than other countries. The three major hurdles that prevent faster and vast progress such as less sustainable behavior change, medication side effects, and medication cost. The Noom GLP-1 program on point identifies all these hurdles and challenges to help defeat the obesity war for many individuals.

Noom’s Program Insights

The Noom’s physician-powered program hires a ‘low and slow’ approach with microdoses that are half of conventional maintenance doses. The data revealed that the members on microdoses encountered destabilizing side effects. Around 70% of noom members consuming microdoses reported no side effects at all. Meanwhile, at the same time, the members successfully lost up to 11 pounds in 30 days and 17 pounds in 60 days at microdose dosages. The standard study witnessed that the majority of patients, around 70% experience side effects.

The program is designed with scientific principles. Its self-efficacy and robust weight loss outcomes, and other health benefits beyond weight loss, are reaching the peak of good and long-life advice to individuals and dieticians, or weight loss experts.

Statements of Groundbreaking Leaders

Chief Medical Officer at Noom, Dr. Jeffrey Egler, said, “The program virtually discards side effects for the majority of people, so more than 70% of individuals don’t face any side effects. In evidence in published studies and clinical experience, it is mentioned that most people discontinued GLP-1 treatment due to the side effects. The noom’s microdose GLP-1 program noticed this issue and launched GLP-1's better and sustainable version to rank at the microdose level.”

Latest Insights